Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Robert W. Baird from $940.00 to $759.00 in a report issued on Wednesday morning,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback